Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.50 |
| ▸ | EGLN3 | Q9H6Z9 | 5/20 | 0.50 |
| ▸ | FTO | Q9C0B1 | 4/20 | 0.50 |
| ▸ | VEGFA | P15692 | 3/20 | 0.47 |
| ▸ | FLT1 | P17948 | 3/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.45 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | CCNC | P24863 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24257788 | 0.88 | KDM4E (0.46) | EGLN1EGLN3FTOVEGFAFLT1 | |
| SCHEMBL30452524 | 0.88 | KDM4E (0.46) | EGLN1EGLN3FTOVEGFAFLT1 | |
| SCHEMBL24257629 | 0.88 | EGLN1 (0.54) | EGLN1EGLN3FTOVEGFAFLT1 | |
| SCHEMBL24257567 | 0.87 | EGLN1 (0.65) | EGLN1EGLN3FTOVEGFAFLT1 | |
| SCHEMBL30454632 | 0.87 | EGLN1 (0.48) | EGLN1EGLN3FTOVEGFAFLT1 | |
| SCHEMBL24257501 | 0.87 | EGLN1 (0.48) | EGLN1EGLN3FTOVEGFAFLT1 | |
| SCHEMBL30453199 | 0.85 | MCL1 (0.53) | MCL1CCNCCDK8 | |
| SCHEMBL24257774 | 0.85 | MCL1 (0.53) | MCL1CCNCCDK8 | |
| SCHEMBL24257636 | 0.82 | EGLN1 (0.51) | EGLN1EGLN3FTOVEGFAFLT1 | |
| SCHEMBL30452742 | 0.82 | EGLN1 (0.51) | EGLN1EGLN3FTOVEGFAFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| CN-116670131-A | PHD inhibitor compounds, compositions, and methods of use | 阿克比治疗有限公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2022036188-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN3, PHF20 | EGLN1 19/4885EGLN3 2/4885FTO 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.